1 min read.Updated: 23 Sep 2020, 12:33 PM ISTReuters
The Phase 3 clinical study of 156 patients in Japan showed that those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group
Fujifilm says it would perform further analysis of the trial data and seek to file for approval of Avigan for use in COVID-19 as early as Oct.
Fujifilm Holdings Corp said on Wednesday a late-stage study of its antiviral drug Avigan showed it reduced recovery times for COVID-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.
The Phase 3 clinical study of 156 patients in Japan showed that those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group. Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant, the company said in a release.
In July, Fujifilm sold its global rights to Avigan to India's Dr Reddy's Laboratories. Already available generically in many countries under the name favipiravir, the drug has been approved to treat COVID-19 in India and Russia.
Avigan acts on the RNA of viruses, inhibiting their ability to replicate. It is the subject of dozens of trials worldwide, but concerns remain over birth defects it caused in animal studies.
Dr Reddy's shares were 0.7% higher at 0430 GMT.
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Never miss a story! Stay connected and informed with Mint.
our App Now!!